The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula I wherein in is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkoxy, benzyloxy, hydroxy, nitro or amino; each R.sub.1 is independently hydrogen, C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6alkenyl, C.sub.1-C.sub.6alkanoyl, halogen, cyano, --C(O)C.sub.1-C.sub.6alkyl, --C.sub.1-C.sub.6alkyleneCN, --C.sub.1-C.sub.6alkyleneNR'R'' wherein R' and R'' are each independently hydrogen or C.sub.1-C.sub.6alkyl, --C.sub.1-C.sub.6alkyleneOC(O)C.sub.1-C.sub.6alkyl, or --CH(OH)R.sub.4 wherein R.sub.4 is hydrogen or C.sub.1-C.sub.6alkyl; R.sub.2 is hydrogen, C.sub.1-C.sub.6alkyl optionally substituted with halogen, hydroxy or benlzyloxy, C.sub.1-C.sub.6alkenyl, C.sub.1-C.sub.6alkynyl, --CO.sub.2C.sub.1-C.sub.6alkyl, or --R.sub.5--NR'R'' wherein R.sub.5 is C.sub.1-C.sub.6alkylene, C.sub.1-C.sub.6alkenylene or C.sub.1-C.sub.6alkynylene and R' and R'' are each independently hydrogen, C.sub.1-C.sub.6alkyl or alternatively the group --NR'R'' as a whole is 1-pyrrolidinyl; and R.sub.3 is hydrogen, nitro, amino, halogen, C.sub.1-C.sub.6alkoxy, hydroxy or C.sub.1-C.sub.6alkyl or a pharmaceutically acceptable salt thereof.